| Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHL (NCT05453669) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2022-06-15 |
| Long-Term Follow-up Study (NCT05332054) | Caribou Biosciences, Inc. | 2022-03-16 |
| CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients. (NCT04697290) | Beijing Tsinghua Chang Gung Hospital | 2022-03-10 |
| HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NCT05190068) | Hutchmed | 2022-01-04 |
| A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (NCT05091541) | Nanjing IASO Biotechnology Co., Ltd. | 2021-10-20 |
| Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma (NCT05436223) | Hrain Biotechnology Co., Ltd. | 2021-08-09 |
| A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NCT05149391) | Peking University | 2021-07-20 |
| CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) (NCT04637763) | Caribou Biosciences, Inc. | 2021-05-26 |
| Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL) (NCT04746131) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2021-01-15 |
| A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma (NCT04655677) | Peking Union Medical College Hospital | 2020-10-30 |
| Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226) (NCT03639181) | Genor Biopharma Co., Ltd. | 2018-10-15 |
| Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Treat B Cell Lymphoproliferative Diseases? (NCT03417414) | Ottawa Hospital Research Institute | 2018-03-01 |
| Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL (NCT02564744) | Debiopharm International SA | 2016-06-05 |
| A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma (NCT02456207) | Sinocelltech Ltd. | 2015-05-01 |
| A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma (NCT02584920) | Shanghai Henlius Biotech | 2014-10-01 |
| Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma. (NCT02206308) | Sinocelltech Ltd. | 2012-05-01 |
| Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia (NCT01351935) | Celgene | 2011-07-18 |
| Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma (NCT01352312) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2011-05-25 |
| A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma (NCT00457782) | Kyowa Kirin Co., Ltd. | 2007-04-01 |
| Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL) (NCT00927797) | Heidelberg University | 2005-02-01 |
| Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL (NCT00588094) | Memorial Sloan Kettering Cancer Center | 2003-10-01 |